SonoThera to Present at ASN Kidney Week 2024 Demonstrating the Potential of Novel Nonviral Ultrasound-Mediated Gene Therapy Delivery Platform
- Presentations confirm potential of delivering targeted gene therapy using SonoThera’s novel, ultrasound-mediated nonviral gene therapy platform.
- Data demonstrates the ability to deliver nucleic acid payloads of diverse formats and sizes non-invasively to targeted organs and tissues in murine models of Hemophilia A and X-linked Alport Syndrome as well as non-human primates (NHP).
- Results highlight the potential use of targeted nonviral nucleic acid delivery resulting in durable gene expression and the ability to re-dose, and dose titrate with exemplary safety and efficacy.
South San Francisco, CA, October 22, 2024 – SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced it will deliver oral and poster presentations at the 31st annual European Society and Gene and Cell Therapy (ESGCT) congress taking place in La Nuvola, Rome, Italy, October 22-25, 2024.
Each presentation features SonoThera’s novel, ultrasound-mediated nonviral gene therapy platform, which is being developed to non-invasively deliver nucleic acid payloads of diverse formats and sizes. While the platform is designed to selectively target a wide range of organs within the body, research presented at ESGCT focuses on its potential in the treatment of Hemophilia A and X-linked Alport Syndrome, and its targeted delivery of re-dosable payloads resulting in robust and durable gene expression in the liver or kidney of murine disease models as well as non-human primates.
“Our presentations demonstrate the potential which targeted, nonviral, ultrasound-mediated gene therapy can offer in diseases where treatment options are either few or insufficient. We look forward to presenting our results at ESGCT,” said Kenneth Greenberg, PhD, CEO of SonoThera.
Session Details:
| Title | Development of a Nonviral Gene Therapy for X-linked Alport Syndrome by Targeted |
|---|---|
| Abstract Number | P0943 |
| Presenter | Ivan Krivega, PhD, Senior Director, Gene Therapy, SonoThera |
| Session Category | Nonviral vectors/Nanotechnology/RNA therapeutics |
| Session Date/Time | Thursday 24 October, 14:00-15:30, Concourse Level -1 and Mezzanine |
| Title | Development of a non-viral genetic medicine for Hemophilia A by targeted transcutaneous |
|---|---|
| Session Number | OR062 (Oral Presentation) |
| Presenter | Ivan Krivega, PhD, Senior Director, Gene Therapy, SonoThera |
| Session Category | SESSION 7b: Hematopoietic, PID and Bleeding II |
| Session Date/Time | Thursday, 24th October 09:00-11:00 · Meeting Room 1 · PARALLEL |
About SonoThera™
Founded by Drs. Kenneth Greenberg, Michael Davidson, and Steve Feinstein, SonoThera, Inc. is a biotechnology company dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-mediated, nonviral gene therapy platform treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. SonoThera is headquartered in South San Francisco, California. Visit
www.sonothera.com to learn more.
| Investor Inquiries | |
|---|---|
| Media Inquiries | Mog & Springer Communications on behalf of SonoThera, Inc. |